Trial Profile

An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide (Primary)
Indications IgA nephropathy
Focus Therapeutic Use
Acronyms COLE; Nefigard-OLE
Sponsors Calliditas Therapeutics

Most Recent Events

26 Oct 2024 Status changed from active, no longer recruiting to completed.
16 Oct 2024 According to a Calliditas Therapeutics media release, data from this study will be presented at the American Society of Nephrology Kidney Week 2024 in San Diego, California on October 23 - 27, 2024.
12 Sep 2024 This trial has been completed in France, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com